DHHS → node
The Maine Prescription Monitoring Program (PMP) is notifying all health care providers and institutions of an abrupt service disruption affecting several hundred patients in southern Maine. A pain and addiction medicine clinic in this region has been affected by federal law enforcement action, leaving patients without access to their usual care.
This is a duplicate posting of an e-message that was sent yesterday, updated to correct a systems issue that impacted a few of the links within the message.
Almost 25% of all new HIV diagnoses are in people ages 45 and older. Older HIV patients have the same risk factors as any age including the following:
Age can make people more prone to HIV. For example, thinning vaginal walls make tears more likely and older people may also be less likely to use a condom since pregnancy is not a concern.
This message is a follow up to our message sent on August 19, 2022. To align with a new enforcement deadline set by Medicare, effective April 1, 2023, MaineCare will deny UB-04 and 837I claims submitted without an enrolled attending provider.
Riverview Psychiatric Center provides state-of-the-art care to individuals in Maine with serious and persistent mental illness and co-occurring disorders.
The Division of Policy posts all proposed and recently adopted rules on MaineCare’s Policy and Rules webpage. This website keeps the propose
MaineCare Services is pleased to announce that we are now accepting applications for participation in MaineCare’s PCPlus program. PCPlus is a MaineCare primary care model that gives Primary Care Providers (PCPs) greater flexibility and incentives to meet MaineCare members’ healthcare needs by transitioning away from a volume-based (fee-for-service) payment system toward population-based payments tied to cost and quality-related outcomes.
The Division of Policy posts all proposed and recently adopted rules on MaineCare’s Policy and Rules webpage. This website keeps the propose
To provide a clear and transparent process for MaineCare rate determinations, with opportunities for robust participation from all interested stakeholders.
Get more information on how you can participate and to view our monthly Rate System Reform updates.
We continue to update this page with important dates and progress made on past, current, and future rate determination work. Please check in often, as this site is a work in progress.
On October 19, 2022, the Food and Drug Administration (FDA) reissued an Emergency Use Authorization letter (EUA) for the use of Monovalent COVID-19 vaccine booster doses from Novavax.